Q-omics provides the consensus-scored ZFP92 profile across patient tissues and cancer cell-line models. ZFP92 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZFP92 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZFP92 RNA expression shows 17,775 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight STAD, HNSC, and PCPG as cancer lineages where ZFP92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP92 survival associations across molecular data types. ZFP92 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP92 RNA expression–survival associations across cancer types. High ZFP92 expression shows unfavorable associations in STAD, BLCA, SKCM, MESO and THCA, but favorable associations in KIRC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for ZFP92 RNA expression.
This table summarizes ZFP92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZFP92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP92 shows lower tumor expression in LUAD, KICH, KIRC, LUSC and UCEC and higher tumor expression in HNSC. The HNSC box plot shows higher ZFP92 RNA expression in tumor versus normal tissue (log2 FC = +1.070, t-test p < 0.001).
This table shows molecular features associated with ZFP92 in patient tissues and cancer cell lines. In patient samples, ZFP92 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
